日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

选择性 HSP90α/β 抑制剂与 RAS-RAF-MEK-ERK 信号通路抑制剂联合使用可在多发性骨髓瘤细胞中引发协同细胞毒性

Rikio Suzuki, Shohei Kikuchi, Takeshi Harada, Naoya Mimura, Jiro Minami, Hiroto Ohguchi, Yasuhiro Yoshida, Morihiko Sagawa, Gullu Gorgun, Diana Cirstea, Francesca Cottini, Jana Jakubikova, Yu-Tzu Tai, Dharminder Chauhan, Paul G Richardson, Nikhil Munshi, Kiyoshi Ando, Teruhiro Utsugi, Teru Hideshima

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition

选择性和有效的 Akt 抑制可触发抗骨髓瘤活性并增强蛋白酶体抑制引起的致命内质网应激

Naoya Mimura, Teru Hideshima, Toshiyasu Shimomura, Rikio Suzuki, Hiroto Ohguchi, Ola Rizq, Shohei Kikuchi, Yasuhiro Yoshida, Francesca Cottini, Jana Jakubikova, Diana Cirstea, Gullu Gorgun, Jiro Minami, Yu-Tzu Tai, Paul G Richardson, Teruhiro Utsugi, Atsushi Iwama, Kenneth C Anderson

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

通过抑制 IRE1α 来阻断 XBP1 剪接是多发性骨髓瘤的一种有希望的治疗选择

Naoya Mimura, Mariateresa Fulciniti, Gullu Gorgun, Yu-Tzu Tai, Diana Cirstea, Loredana Santo, Yiguo Hu, Claire Fabre, Jiro Minami, Hiroto Ohguchi, Tanyel Kiziltepe, Hiroshi Ikeda, Yutaka Kawano, Maureen French, Martina Blumenthal, Victor Tam, Nathalie L Kertesz, Uriel M Malyankar, Mark Hokenson, Tua

Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma

经典和非经典 NF-κB 通路的双重抑制在多发性骨髓瘤中表现出显著的抗肿瘤活性

Claire Fabre, Naoya Mimura, Kathryn Bobb, Sun-Young Kong, Güllü Gorgun, Diana Cirstea, Yiguo Hu, Jiro Minami, Hiroto Ohguchi, Jie Zhang, Jeffrey Meshulam, Ruben D Carrasco, Yu-Tzu Tai, Paul G Richardson, Teru Hideshima, Kenneth C Anderson